AR017440A1 - Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacion - Google Patents
Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacionInfo
- Publication number
- AR017440A1 AR017440A1 ARP980106565A ARP980106565A AR017440A1 AR 017440 A1 AR017440 A1 AR 017440A1 AR P980106565 A ARP980106565 A AR P980106565A AR P980106565 A ARP980106565 A AR P980106565A AR 017440 A1 AR017440 A1 AR 017440A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- phenyl
- fpt inhibitor
- antineoplastic agent
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 3
- -1 4-piperidyl Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 108010092160 Dactinomycin Proteins 0.000 abstract 1
- 108010026389 Gramicidin Proteins 0.000 abstract 1
- 229930126263 Maytansine Natural products 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 abstract 1
- 229940123468 Transferase inhibitor Drugs 0.000 abstract 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 abstract 1
- 229940122803 Vinca alkaloid Drugs 0.000 abstract 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 abstract 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 abstract 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 abstract 1
- 229960001338 colchicine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 abstract 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229960000640 dactinomycin Drugs 0.000 abstract 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 abstract 1
- 229960002694 emetine Drugs 0.000 abstract 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 abstract 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229960003171 plicamycin Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229950010131 puromycin Drugs 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 239000003558 transferase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99602797A | 1997-12-22 | 1997-12-22 | |
| US14352998A | 1998-08-28 | 1998-08-28 | |
| US18196998A | 1998-10-29 | 1998-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017440A1 true AR017440A1 (es) | 2001-09-05 |
Family
ID=27385940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106565A AR017440A1 (es) | 1997-12-22 | 1998-12-21 | Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacion |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1041985B1 (https=) |
| JP (1) | JP4502503B2 (https=) |
| KR (1) | KR100700907B1 (https=) |
| CN (1) | CN1129431C (https=) |
| AR (1) | AR017440A1 (https=) |
| AT (1) | ATE317697T1 (https=) |
| AU (1) | AU756762B2 (https=) |
| BR (1) | BR9814419A (https=) |
| CA (1) | CA2315693C (https=) |
| CL (1) | CL2007001889A1 (https=) |
| CO (1) | CO5080764A1 (https=) |
| CZ (1) | CZ298511B6 (https=) |
| DE (1) | DE69833509T2 (https=) |
| DK (1) | DK1041985T3 (https=) |
| ES (1) | ES2255196T3 (https=) |
| HU (1) | HUP0102473A3 (https=) |
| IL (1) | IL136462A0 (https=) |
| MY (1) | MY137303A (https=) |
| NO (1) | NO326832B1 (https=) |
| NZ (1) | NZ504928A (https=) |
| PE (1) | PE20000042A1 (https=) |
| PT (1) | PT1041985E (https=) |
| SK (1) | SK285584B6 (https=) |
| TW (1) | TW581763B (https=) |
| WO (1) | WO1999032114A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2787327B1 (fr) * | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| CZ20021550A3 (cs) * | 1999-11-09 | 2003-02-12 | Societe De Conseils De Recherches Et D'application | Produkt zahrnující inhibitor transdukce signálů heterotrimerického G proteinu kombinovaný s jiným protirakovinným činidlem pro terapeutické použití v léčbě rakoviny |
| WO2001045740A2 (en) * | 1999-12-22 | 2001-06-28 | The Government Of The United States, Department Of Health And Human Services | Compositions and methods for treatment of breast cancer |
| US20030027808A1 (en) * | 2000-02-29 | 2003-02-06 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| EP1261343A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| US20030078281A1 (en) * | 2000-02-29 | 2003-04-24 | Rybak Mary Ellen Margaret | Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents |
| EP1267871A2 (en) * | 2000-02-29 | 2003-01-02 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| WO2001064196A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| AU2001244167A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| WO2002056884A2 (en) * | 2001-01-22 | 2002-07-25 | Schering Corporation | Treatment of malaria with farnesyl protein transferase inhibitors |
| JP4969016B2 (ja) * | 2001-02-15 | 2012-07-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物 |
| CN1617755A (zh) * | 2001-11-30 | 2005-05-18 | 先灵公司 | 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 |
| CA2468996A1 (en) * | 2001-12-03 | 2003-06-12 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| WO2008022535A1 (fr) * | 2006-08-09 | 2008-02-28 | Tian Jin Tasly Group Co., Ltd. | Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique |
| CN105198758A (zh) * | 2015-09-22 | 2015-12-30 | 湖南大学 | 一种高纯度(z)-他莫昔酚的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| WO1992011034A1 (en) * | 1990-12-18 | 1992-07-09 | The Wellcome Foundation Limited | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
| JP2767176B2 (ja) * | 1992-12-15 | 1998-06-18 | 大塚製薬株式会社 | 抗癌剤 |
| US5637688A (en) * | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
| DE69635114T2 (de) * | 1995-08-09 | 2006-03-02 | Banyu Pharmaceutical Co., Ltd. | Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids |
| IL125062A (en) * | 1995-12-22 | 2003-11-23 | Schering Corp | Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases |
| CN1304058C (zh) * | 1996-03-12 | 2007-03-14 | Pg－Txl有限公司 | 水溶性紫杉醇产品 |
| EP0959883A4 (en) * | 1996-04-03 | 2001-05-09 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| US20020034725A1 (en) * | 1996-04-15 | 2002-03-21 | W. Gillies Mckenna | Sensitization of cells to radiation and and chemotherapy |
| CA2251955A1 (en) * | 1996-04-18 | 1997-10-23 | Nancy E. Kohl | A method of treating cancer |
| EP0934270A1 (en) * | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
| US6337992B1 (en) * | 1997-01-29 | 2002-01-08 | Philips Medical Systems Technologies Ltd. | Predictive bolus tracking |
| IL131447A0 (en) * | 1997-02-18 | 2001-01-28 | Canji Inc | Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms |
-
1998
- 1998-12-21 DK DK98963829T patent/DK1041985T3/da active
- 1998-12-21 PE PE1998001263A patent/PE20000042A1/es not_active Application Discontinuation
- 1998-12-21 SK SK898-2000A patent/SK285584B6/sk not_active IP Right Cessation
- 1998-12-21 EP EP98963829A patent/EP1041985B1/en not_active Expired - Lifetime
- 1998-12-21 AR ARP980106565A patent/AR017440A1/es unknown
- 1998-12-21 HU HU0102473A patent/HUP0102473A3/hu unknown
- 1998-12-21 KR KR1020007006938A patent/KR100700907B1/ko not_active Expired - Fee Related
- 1998-12-21 DE DE69833509T patent/DE69833509T2/de not_active Expired - Lifetime
- 1998-12-21 CA CA2315693A patent/CA2315693C/en not_active Expired - Fee Related
- 1998-12-21 TW TW087121355A patent/TW581763B/zh not_active IP Right Cessation
- 1998-12-21 AU AU19072/99A patent/AU756762B2/en not_active Ceased
- 1998-12-21 WO PCT/US1998/026224 patent/WO1999032114A1/en not_active Ceased
- 1998-12-21 CN CN98813742A patent/CN1129431C/zh not_active Expired - Fee Related
- 1998-12-21 AT AT98963829T patent/ATE317697T1/de not_active IP Right Cessation
- 1998-12-21 MY MYPI98005809A patent/MY137303A/en unknown
- 1998-12-21 NZ NZ504928A patent/NZ504928A/xx unknown
- 1998-12-21 CZ CZ20002236A patent/CZ298511B6/cs not_active IP Right Cessation
- 1998-12-21 CO CO98075842A patent/CO5080764A1/es unknown
- 1998-12-21 ES ES98963829T patent/ES2255196T3/es not_active Expired - Lifetime
- 1998-12-21 PT PT98963829T patent/PT1041985E/pt unknown
- 1998-12-21 JP JP2000525105A patent/JP4502503B2/ja not_active Expired - Fee Related
- 1998-12-21 IL IL13646298A patent/IL136462A0/xx unknown
- 1998-12-21 BR BR9814419-7A patent/BR9814419A/pt not_active Application Discontinuation
-
2000
- 2000-06-21 NO NO20003229A patent/NO326832B1/no not_active IP Right Cessation
-
2007
- 2007-06-27 CL CL2007001889A patent/CL2007001889A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR017440A1 (es) | Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacion | |
| ATE495793T1 (de) | Antitumorzusammensetzungen welche ecteinascidin 743 enthalten | |
| GEP20032896B (en) | 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment | |
| FR2678938B1 (fr) | Derives de pyrrolidine, leur preparation et les medicaments les contenant. | |
| IL80149A (en) | Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases | |
| CY1106602T1 (el) | Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων | |
| ATE79619T1 (de) | Arzneimittel. | |
| GEP20063799B (en) | Tropane derivatives useful in therapy | |
| DK0776202T3 (da) | Liposomalt indkapslet taxol, dets fremstilling af dets anvendelse | |
| FI863652A0 (fi) | 7-isopropoxiisflavoninklusionskomplex bildat med cyklodextrin och ett foerfarande foer dess framstaellning. | |
| CY1111153T1 (el) | Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης | |
| ES2037086T3 (es) | Procedimiento para preparar formulaciones farmaceuticas. | |
| CY1109364T1 (el) | Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες | |
| AR043071A1 (es) | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica | |
| FI895520A0 (fi) | Anti-aterosklerotiska diaryl foereningar. | |
| NO304113B1 (no) | Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament | |
| DK0539479T3 (da) | Heterocykliske forbindelser | |
| DE69215999D1 (de) | Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs | |
| ES2135342B1 (es) | Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama. | |
| IL88971A0 (en) | Disubstituted pyridines,their preparation and pharmaceutical compositions containing them | |
| IL141515A (en) | Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same | |
| ITRM930286A0 (it) | Composizione farmaceutica per somministrazione rettale nel trattamentodi cefaleo e relativo metodo di preparazione ed impiego. | |
| MY114282A (en) | Anthracycline derivatives | |
| AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion | |
| GEP20043225B (en) | 1-Trifluoromethyl-4-Hydroxy-7- Piperidinyl-Aminomethylchroman Derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |